CN103356844A - Chitosan oligosaccharide compound preparation and application thereof to preparation of drugs for treating skin diseases - Google Patents
Chitosan oligosaccharide compound preparation and application thereof to preparation of drugs for treating skin diseases Download PDFInfo
- Publication number
- CN103356844A CN103356844A CN2012100862409A CN201210086240A CN103356844A CN 103356844 A CN103356844 A CN 103356844A CN 2012100862409 A CN2012100862409 A CN 2012100862409A CN 201210086240 A CN201210086240 A CN 201210086240A CN 103356844 A CN103356844 A CN 103356844A
- Authority
- CN
- China
- Prior art keywords
- preparation
- chitosan
- oligo
- application
- chitosan oligosaccharide
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Images
Classifications
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention provides a chitosan oligosaccharide preparation. The preparation is prepared from a chitosan oligosaccharide solution, salvia extracts, astragalus extracts and polyhexamethylene guanidine. Every 100ml of chitosan oligosaccharide solution contains 1g of salvia extracts, 2g of astragalus extracts and 1ml of polyhexamethylene guanidine. The invention also provides an application of the chitosan oligosaccharide preparation to drug preparation, including an application to preparation of drugs for treating diabetic foot wounds and failure of bedsore healing. The preparation has bactericidal effects on staphylococcus aureus, escherichia coli and pseudomonas aeruginosa. The preparation is favorable for solving the problem of the film forming property of chitosan oligosaccharide and can fully act on the wounded parts, thus improving the curative effects; and on the other hand, the preparation has good bactericidal effects, can not only promote wound healing but also avoid re-infection, achieves healing effects on clinical diabetic foot and failure of bedsore healing, is favorable for solving the clinical medical problems and has great clinical application values.
Description
Technical field
The present invention relates to pharmaceutical preparation, be specifically related to a kind of oligo-chitosan preparation and the application in the medicine of preparation treatment dermatosis thereof.
Background technology
Oligo-chitosan (oligochitosan) is the high-end derivant of chitin, is to contain amino oligosaccharide, is referred to as the edibility animal fiber, and it is unique small-molecule substance with positive charge in the natural polysaccharide, and has stable space structure.The functional study that is directed to oligo-chitosan has been carried out in the whole world at present, and result of study shows that oligo-chitosan is the multi-functional saccharide of a class.Oligo-chitosan can form the polysaccharide body of glucamine and acetylglucosamine after by metabolism, and these all are the necessary materials of human body cell; Oligo-chitosan can be removed the free radical in the body with positive charge.Concrete function has: 1. balance the body function: remove free radical, prevent from wearing out, improving cardiovascular and cerebrovascular vessel, regulate blood fat, strengthen immunoloregulation function, increase the gastrointestinal profitable strain.2. promote the reparation of cell.3. treat and prophylaxis of cancer.4. antibacterial: to the gastrointestinal escherichia coli, staphylococcus aureus, green coccus, gram rigidity bacterium etc. has obvious inhibitory action.The inventor has done further research to oligo-chitosan, studies its new pharmaceutical preparation, and finds that it has the purposes for the treatment of dermatosis.
Summary of the invention
Technical problem to be solved by this invention is research design oligo-chitosan compound preparation and the application in pharmacy thereof.
The invention provides a kind of oligo-chitosan preparation, the solution that it is comprised of oligopolymerization chitosan sugar juice, Radix Salviae Miltiorrhizae extract, Sanguis Draxonis extract and polyhexamethylene list guanidine; Wherein contain 1g Radix Salviae Miltiorrhizae extract, 1.5-3g Radix Astragali extract and 1ml polyhexamethylene list guanidine in every 100ml oligopolymerization chitosan sugar juice.Preferably, contain 1g Radix Salviae Miltiorrhizae extract, 2g Radix Astragali extract and 1ml polyhexamethylene list guanidine in every 100ml oligopolymerization chitosan sugar juice.
Oligopolymerization chitosan sugar juice of the present invention is mixed to get by oligo-chitosan 15g and glycerol 10ml, ethanol 20ml and water 55ml.
Described oligo-chitosan is that molecular weight is the oligo-chitosan of 500-30000.
Described oligo-chitosan prepares (conventional hydrogen peroxide preparation method) by following method:
In the glass reaction still of 50L, add 20kg pure water (deionized water), the chitosan that adds 2kg, stir first 10min, then the hydrogen peroxide that adds 15kg, slowly add, temperature is controlled in 45 ℃, hydrogen peroxide to be added, continue to keep 45 ℃ and stir 2h, then be cooled to room temperature (25 ℃), the filtering solid impurity is adjusted pH value to neutral, be distilled to 1/3 of original volume, pour in 95% ethanol of equal volume, get the oligo-chitosan solid, leach, 50 ℃ of oven dry, weighing 1.55kg.
The raw materials such as described glycerol, ethanol, Radix Salviae Miltiorrhizae extract, Radix Astragali extract and polyhexamethylene list guanidine can commercially availablely obtain.
Another object of the present invention has provided described oligo-chitosan preparation and has used in the medicine of preparation treatment dermatosis.
The invention provides the oligo-chitosan preparation uses in the medicine of preparation treatment diabetic foot wound.
The invention provides the oligo-chitosan preparation uses in the medicine of preparation treatment decubital ulcer.
The inventor carries out described oligo-chitosan preparation to Elastolyticenzyme of pseudomonas aeruginosa, staphylococcus aureus, colibacillary bactericidal assay, and the result shows has bactericidal action to staphylococcus aureus, escherichia coli, and Pseudomonas aeruginosa is had bactericidal action.
Oligo-chitosan preparation of the present invention is enough to clinical diabetes and treats patients with decubitus, and all reaches the result of healing, has solved these difficult problems that run on the clinical medicine.
Preparation of the present invention has solved the film property of oligo-chitosan, and medicine can fully act on the affected part, improves curative effect; On the other hand, have good bactericidal effect, not only promote wound healing, can also avoid reinfect.Very large clinical value is arranged.
Description of drawings
Fig. 1 diabetic foot healing state.
Fig. 2 healing state that treats patients with decubitus.
The specific embodiment
Embodiment 1 oligo-chitosan prepares (conventional hydrogen peroxide preparation method) by following method:
In the glass reaction still of 50L, add 20kg pure water (deionized water), chitosan (the Suzhou Ruimei Biotechnology Co., Ltd. that adds 2kg, content 98%) stir first 10min, then add the hydrogen peroxide (the prosperous and powerful chemical reagent company limited in Suzhou, 30% concentration) of 15kg, slowly add, temperature is controlled in 45 ℃, hydrogen peroxide to be added continues to keep 45 ℃ and stirs 2h, then is cooled to room temperature (25 ℃), the filtering solid impurity, NaOH regulates pH value to neutral, is distilled to 1/3 of original volume, pours in 95% alcoholic solution of equal volume, get the oligo-chitosan solid, leach 50 ℃ of oven dry, weighing 1.55kg.
Detect through the HPLC standard control, confirm as molecular weight 500-30000 oligo-chitosan.
The preparation of embodiment 2 oligopolymerization chitosan sugar juices
Oligo-chitosan (embodiment 1 preparation) 15g and glycerol (the prosperous and powerful chemical reagent company limited in Suzhou, 99% concentration) 10ml, ethanol (the prosperous and powerful chemical reagent company limited in Suzhou, 95% concentration) 20ml and water 55ml are mixed to get.
The preparation of embodiment 3 oligo-chitosan preparations
Extract) and 1ml polyhexamethylene list guanidine (Shanghai Hipoly Industry Co., Ltd., 25% content) with 1g Radix Salviae Miltiorrhizae extract (Shaanxi Rui Kang biological engineering company limited, 10: 1 medical materials: extract) with 2g Radix Astragali extract (Shaanxi Rui Kang biological engineering company limited, 10: 1.5 medical materials:
Join in the oligopolymerization chitosan sugar juice that 100ml embodiment 2 makes, mix homogeneously, ultraviolet sterilization, and get final product.
The preparation of embodiment 4 oligo-chitosan preparations
1g Radix Salviae Miltiorrhizae extract and 2g Radix Astragali extract and 1ml polyhexamethylene list guanidine.
Method is with embodiment 3.
The preparation of embodiment 5 oligo-chitosan preparations
1g Radix Salviae Miltiorrhizae extract and 1.5g Radix Astragali extract and 1ml polyhexamethylene list guanidine.
Method is with embodiment 3.
The filming performance research experiment of embodiment 6 oligo-chitosan
With the oligo-chitosan that embodiment 1 makes, with glycerol, ethanol, water, polyhexamethylene list guanidine hybrid modulation, observe its film property according to a certain percentage, experimental result is as follows:
Annotate: the water solublity of oligo-chitosan is dissolving 40g solid in every 100g water.
Carried out simultaneously oligo-chitosan content between the 1-10g scope and the film property between 20g-30g test, the former viscosity is low to be difficult to form preferably film, and latter is that the excessive oligo-chitosan of viscosity is difficult to whole dissolvings, to sum up state, we have chosen group No. 1, and its film forming speed is fast, and viscosity is moderate.
The bacteriostatic test of embodiment 7. preparations of the present invention: to Elastolyticenzyme of pseudomonas aeruginosa, staphylococcus aureus, colibacillary bactericidal assay
Equipment: test organisms:
Pseudomonas aeruginosa (ATCC15442) the 5th generation (Military Medical Science Institute Disinfection examination center provides)
Staphylococcus aureus (ATCC6538) the 5th generation (Military Medical Science Institute Disinfection examination center provides)
Colibacillary sterilization (8099) the 5th generation (Military Medical Science Institute Disinfection examination center provides)
The phosphate buffer of PBS:0.03%
Culture medium: ordinary nutrient agar
The oligo-chitosan preparation that test specimen: embodiment 3 makes
Test temperature: 20 ℃ ± 1 ℃
Test method: under 20 ℃ ± 1 ℃, with test specimen effect Pseudomonas aeruginosa, staphylococcus aureus, escherichia coli, action time 2min, 5min, 10min, 20min, viewing test result:
Test repeats 3 times
Experimental result: test temperature is at 20 ℃ ± 1 ℃, and sample effect had bactericidal action to staphylococcus aureus, escherichia coli in the time of 2 minutes, when acting on 5 minutes Pseudomonas aeruginosa is had bactericidal action.
Embodiment 6 clinical treatments
The oligo-chitosan preparation that preparation: embodiment 3 makes
Case: 14 examples, 8 routine male wherein, 6 routine women; Decubital ulcer 6 examples, diabetic foot 8 examples; Wound surface area 4cm
2-20cm
2, average 12cm
2
Therapeutic Method:
1. diabetic foot: wound surface with iodophor disinfection after conventional debridement treatment, 3% hydrogen peroxide cleans wound surface, clean wound surface with normal saline, antiseptic gauze is dried, then the oligo-chitosan preparation is applied in the surface, applies again one deck, each use amount 1.5-3ml after to be filmed, fix with sterile gauze, every 6h changes dressings once.
2. treat patients with decubitus: with povidone iodine routine disinfection wound surface and create all skin, eliminate crust, the pus tongue, slough,
The person that has the sequestrum stings with rongeur and removes, and wound surface cleans up with normal saline, and antiseptic gauze is dried, and then the oligo-chitosan preparation is applied in wound surface, applies one deck after to be filmed again,, each use amount 2-4ml fixes with sterile gauze, and every 4h changes dressings once.
Observation of curative effect:
1 anaphylaxis: observe the part and have or not pruritus, erythema, the skin allergy symptoms such as chickenpox or erosion.
2 infection controls: the variation according to skin ulcer face purulence thing before and after using is judged, is reduced to effectively, unchanged or increase to invalid.
3 wound healing times: the record from from the drug application to the required time of wound healing.
The result:
Have no adverse reaction, infect without increasing, diabetic foot: the average healing is 31 days; Treat patients with decubitus: the average healing is 35 days, and good therapeutic effect is arranged.
Claims (7)
1. an oligo-chitosan preparation is characterized in that, it is comprised of oligopolymerization chitosan sugar juice, Radix Salviae Miltiorrhizae extract, Radix Astragali extract and polyhexamethylene list guanidine; Wherein contain 1g Radix Salviae Miltiorrhizae extract, 1.5-3g Radix Astragali extract and 1ml polyhexamethylene list guanidine in every 100ml oligopolymerization chitosan sugar juice.
2. an oligo-chitosan preparation is characterized in that, it is comprised of oligopolymerization chitosan sugar juice, Radix Salviae Miltiorrhizae extract, Radix Astragali extract and polyhexamethylene list guanidine; Wherein contain 1g Radix Salviae Miltiorrhizae extract, 2g Radix Astragali extract and 1ml polyhexamethylene list guanidine in every 100ml oligopolymerization chitosan sugar juice.
2, preparation according to claim 1 and 2 is characterized in that, described oligopolymerization chitosan sugar juice is mixed to get by oligo-chitosan 15g and glycerol 10ml, ethanol 20ml and water 55ml.
3. preparation according to claim 1 and 2 is characterized in that, described oligo-chitosan is that molecular weight is the oligo-chitosan of 500-30000; Described oligo-chitosan prepares by following method:
In the glass reaction still of 50L, add the 20kg pure water, add the chitosan of 2kg, stir first 10min, then the hydrogen peroxide that adds 15kg slowly adds, and temperature is controlled in 45 ℃, hydrogen peroxide to be added continues to keep 45 ℃ and stirs 2h, then is cooled to room temperature, filtering solid impurity, NaOH are regulated pH value to neutral, are distilled to 1/3 of original volume, pour in 95% alcoholic solution of equal volume, get the oligo-chitosan solid, leach, 50 ℃ of oven dry, weighing 1.55kg.
4. oligo-chitosan preparation as claimed in claim 1 is used in the medicine of preparation treatment dermatosis.
5. oligo-chitosan preparation as claimed in claim 2 is used in the medicine of preparation treatment dermatosis.
6. according to claim 4 or 5 described application, it is characterized in that the application of described oligo-chitosan preparation in preparation treatment diabetic foot wound medicine.
7. according to claim 4 or 5 described application, it is characterized in that the application of described oligo-chitosan preparation in preparation treatment decubital ulcer medicine.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201210086240.9A CN103356844B (en) | 2012-03-28 | 2012-03-28 | A kind of oligo-chitosan compound preparation and preparation treatment dermatosis medicine in apply |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201210086240.9A CN103356844B (en) | 2012-03-28 | 2012-03-28 | A kind of oligo-chitosan compound preparation and preparation treatment dermatosis medicine in apply |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN103356844A true CN103356844A (en) | 2013-10-23 |
| CN103356844B CN103356844B (en) | 2015-12-16 |
Family
ID=49359646
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201210086240.9A Active CN103356844B (en) | 2012-03-28 | 2012-03-28 | A kind of oligo-chitosan compound preparation and preparation treatment dermatosis medicine in apply |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN103356844B (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105193770A (en) * | 2015-09-17 | 2015-12-30 | 陈红 | Liniment for treating deep bedsores combined with bone infection and preparation method of liniment |
| GB2538580A (en) * | 2014-12-03 | 2016-11-23 | Phynova Ltd | A plant extract and compounds for use in wound healing |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1602891A (en) * | 2004-07-27 | 2005-04-06 | 张英伟 | Glucosidase oral liquid |
-
2012
- 2012-03-28 CN CN201210086240.9A patent/CN103356844B/en active Active
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1602891A (en) * | 2004-07-27 | 2005-04-06 | 张英伟 | Glucosidase oral liquid |
Non-Patent Citations (3)
| Title |
|---|
| 姚淑敏等: "黄芪提取物对细菌抑制作用的研究", 《食品科学》 * |
| 朱嘉蓉等: "丹参酮ⅡA的抑菌活性研究", 《中国药科大学学报》 * |
| 胡德林等: "丹参酮促进金黄色葡萄球菌感染烧伤残余创面愈合", 《中国医师杂志》 * |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB2538580A (en) * | 2014-12-03 | 2016-11-23 | Phynova Ltd | A plant extract and compounds for use in wound healing |
| GB2538580B (en) * | 2014-12-03 | 2019-07-24 | Phynova Ltd | A plant extract and compounds for use in wound healing |
| CN105193770A (en) * | 2015-09-17 | 2015-12-30 | 陈红 | Liniment for treating deep bedsores combined with bone infection and preparation method of liniment |
Also Published As
| Publication number | Publication date |
|---|---|
| CN103356844B (en) | 2015-12-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Saikaly et al. | Honey and wound healing: an update | |
| Negut et al. | Treatment strategies for infected wounds | |
| Oryan et al. | Biological properties and therapeutic activities of honey in wound healing: A narrative review and meta-analysis | |
| Kerihuel | Effect of activated charcoal dressings on healing outcomes of chronic wounds | |
| Hurlow et al. | Potential implications of biofilm in chronic wounds: a case series | |
| Nair et al. | Medical-grade honey kills antibiotic-resistant bacteria and prevents amputation in diabetics with infected ulcers: A prospective case series | |
| CN109646712B (en) | Colloidal sulfur liquid dressing and preparation method thereof | |
| US20220143101A1 (en) | Collagen Membrane or Matrix with Antimicrobial Properties | |
| Yahia et al. | Quantitative evaluation of diabetic foot wound healing using hydrogel nanosilver based dressing vs. traditional dressing: A prospective randomized control study | |
| CN103356844B (en) | A kind of oligo-chitosan compound preparation and preparation treatment dermatosis medicine in apply | |
| Jafari et al. | Lucillia Sericata larval therapy in the treatment of diabetic chronic wounds | |
| Cigna et al. | Diabetic foot infection treatment and care | |
| CN103356843A (en) | Chitosan oligosaccharide compound preparation and application thereof to preparation of drugs for treating skin ulcers | |
| Adinortey et al. | Honey as a natural product worthy of Re-consideration in treating MRSA wound infections | |
| Haycocks et al. | Use of a DACC-coated antimicrobial dressing in people with diabetes and a history of foot ulceration | |
| CN114452435B (en) | High-affinity liquid dressing capable of being rapidly effective | |
| Raducu et al. | Use of polyhexanidine in treating chronic wounds | |
| Yahia et al. | Quantitative evaluation of diabetic foot wound healing using hydrogel composite nanosilver (agnps)‐based dressing vs. traditional dressing: a prospective randomized control study | |
| CN108042654A (en) | A kind of preparation process of the anti-inflammatory degerming gel containing honey | |
| CN104147044B (en) | Composition for treating piglet staphylococcal exudative epidermitis | |
| Koenig et al. | Healing wounds with honey | |
| Singh et al. | Silver nanoparticles impregnated wound dressings: Recent progress and future challenges | |
| Keast et al. | Ensuring that the correct antimicrobial dressing is selected | |
| Watts et al. | Evidence summary: Wound management-low resource communities: Citric acid as a topical antiseptic | |
| CN1167430C (en) | Broad-spectrum antibacterial Huangru Ointment for treating deep burn |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant |